NovImmune S.A.

5 trials 3 recruiting Commercial sponsor Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

1 Completed trials

3 Countries active

0 Unique IMPs

100% Results reported

Phase I

Phase I (Other)

Phase I: 4 Phase I (Other): 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

All trials

5 total

A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Not authorised

2023-508058-24-00 Phase I 1 country
A PHASE I STUDY OF XXX AS SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN SOLID CANCERS AND A RANDOMIZED COHORT EXPLORING THE COMB… Recruiting

2024-512175-12-00 Phase I 1 country
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Recruiting

2023-508058-24-01 Phase I 1 country
A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel al… Recruiting

2024-517752-35-00 Phase I 3 countries
A PHASE 1B, OPEN-LABEL, DOSE ESCALATION WITH AN EXPANSION TRIAL OF A IN COMBINATION WITH B OR A PLUS STANDARD OF CARE IN PATIENTS WITH XXX C… Ended

2025-521582-27-00 Phase I (Other) 1 country

Showing 1–5 of 5 trials

← All sponsors A–Z